• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Celldex Therapeutics (NQ: CLDX )

    37.57 -1.21 (-3.12%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 457,054
    Open 38.73
    Bid (Size) 37.00 (1)
    Ask (Size) 50.00 (5)
    Prev. Close 38.78
    Today's Range 37.43 - 39.40
    52wk Range 22.11 - 53.18
    Shares Outstanding 65,910,548
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Analyst Expectations For Celldex Therapeutics's Future
    Via Benzinga
    Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -7.03%
    -7.03%
    1 Month
    +7.62%
    +7.62%
    3 Month
    -5.20%
    -5.20%
    6 Month
    -5.39%
    -5.39%
    1 Year
    +3.13%
    +3.13%

    More News

    Read More
    Celldex Therapeutics to Present at Jefferies Healthcare Conference
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    Analyst Expectations For Celldex Therapeutics's Future
    Via Benzinga
    Unveiling 4 Analyst Insights On Celldex Therapeutics
    Via Benzinga
    Celldex Therapeutics: Q4 Earnings Insights
    Via Benzinga
    Forecasting The Future: 5 Analyst Projections For Celldex Therapeutics
    Via Benzinga
    Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    Celldex Therapeutics Announces Proposed Public Offering of Common Stock
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatment
    Via Investor's Business Daily
    Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
    From Celldex Therapeutics, Inc.
    Via GlobeNewswire
    Top Picks 2024: Celldex Therapeutics, Inc.
    Via Talk Markets
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.